Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes...
14 insider purchases on record · latest filing 2025-05-13.
Insiders have also filed 109 sale transactions at GERN.